Nasdaq Markets

The coronavirus’ grip on the market continues. Since the beginning of February, the S&P 500 has shed 8.5% of its value, a reflection of the effect the outbreak is having on the global economy. Amidst the bloodbath, one specific group of stocks is holding up. These are the drug companies those infected, the public at large and investors are hoping can halt the virus from spreading any further. Gilead Sciences (GILD) is among those leading the search for a treatment and is currently being rewarded by the market. In contrast to the broader market, GILD stock is up 23% year-to-date.

Remdesivir, one of the company’s existing drugs which was previously tested as a possible treatment for Ebola, is being tested as a potential treatment for COVID-19.

Gilead has initiated two Phase III studies in China, one in severe patients and one in patients with moderate symptoms. The trials will have short endpoints (14 days), with the possibility of data readouts in April.

In addition to the coronavirus developments, Gilead also recently announced it will acquire immuno-oncology specialist Forty Seven, in a deal worth $4.9 billion.

While Jefferies’ Michael Yee remains positive on Gilead’s prospects, the 4-star analyst tempers expectations of the drug’s financial impact. “We applaud the efforts - but reiterate while this is fundamentally positive, the financial implications are modest (pricing, one-time use, no tail). Also, in our discussions, while GILD is hopeful on the efficacy, they caution CV should not be a key driver to valuation, since it is mostly humanitarian and unlikely to drive any material benefits. In our math, even at a $1,000-5,000 price x 500,000 estimate points, this is $500 million-$2 billion-plus but GILD has been known to give away aid to regions at cost,” said Yee

Yee reiterated a Buy on Gilead, along with a price target of $76. Gilead’s recent surge means the figure currently implies possible downside of 5.26%. (To watch Yee’s track record, click here)

Maxim Group’s Jason McCarthy is also skeptical of the drug’s ability to drive profit.

The analyst noted, “The coronavirus threat is real, and it should be a concern to the public-no question. However, from an investing perspective, we view remdesivir as a relatively modest opportunity at best for Gilead, and not a growth driver. That said, we are not at all minimizing Gilead's efforts to rapidly advance remdesivir to see if they have a drug for coronavirus that could save lives. Actually, the company's efforts are impressive to say the least. We are looking at it purely through the lens of the value proposition and the growth prospects of the company; fundamentals vs. hype.”

Accordingly, McCarthy remains on the fence and maintains his Hold rating. The analyst currently has no price target. (To watch McCarthy’s track record, click here)

The Street’s take on the virus fighter is currently split almost evenly down the middle. 9 Buys, 9 Holds and 1 Sell add up to a Moderate Buy consensus rating. The average price target is $75.94 and implies that the analysts see the stock dropping 5.34% from current levels. (See Gilead stock-price forecast on TipRanks)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Medical debt is not just a burden for countless Americans; it's also the No. 1 source of personal bankruptcy filings in the country. But for some lucky folks, relief may be around the corner. 

When it comes to your Social Security benefits, you have a lot of choices regarding when to start getting those monthly checks. In fact, most retirees could begin getting benefits as early as their 62nd birthday or could opt to wait and claim benefits any time up to age 70. Thos

The global COVID-19 outbreak has everyone thinking about what could happen if the disease spreads more fully across the general population. Despite best efforts to contain the outbreak, people in dozens of countries around the world have contracted the virus. That points to the

If there's one person investors should listen to during a market correction, it's Warren Buffett. At age 89, Buffett has lived through quite a few downturns. And he's made out pretty well: His net worth is in the ballpark of $85 billion. 

Are you dreaming of giving notice at your job and beginning a life of leisure as a retiree? Before you do, make sure you're financially prepared, otherwise this dream could turn into a nightmare. 

Last week, the stock market experienced its worst week since 2008. The culprit for that long-awaited correction was none other than the COVID-19 epidemic. The coronavirus keeps spreading worldwide and is threatening to become a full-blown pandemic.

By Jeff Miller:

Image source: The Motley Fool.

Recently, the state of Michigan started getting serious about where dispensaries source their product. On March 2, the state finally began a process that will phase individual caregivers out of the market.

What happened Shares of Dropbox (NASDAQ: DBX) rose 14.9% in February 2020, according to data from S&P Global Market Intelligence. The provider of cloud-based file hosting services and other lightweight productivity tools posted a modest earnings surprise last month, but the

What happened Shares of Bilibili (NASDAQ: BILI) rose 19.2% in February 2020, according to data from S&P Global Market Intelligence. The Chinese short-form video service emerged as a positive play on the coronavirus outbreak.

What happened Shares of T-Mobile US (NASDAQ: TMUS) rose 13.9% in February, according to data from S&P Global Market Intelligence. The North American cell network operator cleared the last major hurdle on the way to completing a merger with smaller rival Sprint (NYSE: S).

If you have access to a 401(k) at work, chances are that this will be one of your most important retirement accounts, if not the most. Many workers put most or all of their retirement savings into a 401(k), which can make sense because it's convenient, comes with generous tax sa

The content catalog at Netflix (NASDAQ: NFLX) keeps widening, but a new reality show has been one of its top draws for weeks. Love Is Blind has vaulted to the top spot in the U.S. over the weekend, even though the three-week event concluded more than a week ago. 

The coronavirus continued to be the main headline across the world this week. Fears about how the virus will affect businesses led to more market volatility as stocks moved up and down viciously.

Harvest Health & Recreation (OTC: HRVSF) is set to open three dispensaries in Ohio, following a settlement with state regulators.

Laboratory Corporation of America (NYSE: LH) and Quest Diagnostics (NYSE: DGX) recently announced the launch of testing services for COVID-19, the disease caused by the novel coronavirus. LabCorp's test has been available since Thursday, while Quest will begin testing on Monda

It's been a rough couple of weeks for Tesla (NASDAQ: TSLA) stock. But long-term shareholders in the electric-car maker are likely to be easily brushing off the pullback's impact to their portfolios. After all, shares are still up considerably from where they were just six months

The coronavirus scare is closing down music festivals. On Friday, the City of Austin shut down the South By Southwest (SXSW) festival in Austin, Texas. The Ultra Music Festival in Miami, Florida was canceled earlier this week.